This is underlined by observations in preclinical studies of enoticumab combined with the anti-VEGF IgG1 Fc-fusion (aflibercept) in different cancer models (132, 133), ABT-165 in mouse xenografts (103) and in clinical studies of navicixizumab (93). This evidence concerns the gene VEGFA and cancer.